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Cells express distinct G protein-coupled receptor (GPCR)
subtypes on their surface, allowing them to react to a corre-
sponding variety of extracellular stimuli. Cross-regulation
between different ligand-GPCR pairs is essential to generate
appropriate physiological responses. GPCRs can physically
affect each other’s functioning by forming heteromeric com-
plexes, whereas cross-regulation between activated GPCRs also
occurs through integration of shared intracellular signaling net-
works. Human herpesviruses utilize virally encoded GPCRs to
hijack cellular signaling networks for their own benefit. Previ-
ously, we demonstrated that the Epstein-Barr virus-encoded
GPCR BILF1 forms heterodimeric complexes with human che-
mokine receptors. Using a combination of bimolecular comple-
mentation and bioluminescence resonance energy transfer
approaches, we now show the formation of hetero-oligomeric
complexes between this viral GPCR and human CXCR4. BILF1
impaired CXCL12 binding to CXCR4 and, consequently, also
CXCL12-induced signaling. In contrast, the G protein uncou-
pled mutant BILF1-K3.50A affected CXCL12-induced CXCR4
signaling to a much lesser extent, indicating that BILF1-medi-
atedCXCR4 inhibition is a consequence of its constitutive activ-
ity. Co-expression of Gi1 with BILF1 and CXCR4 restored
CXCL12-induced signaling. Likewise, BILF1 formed hetero-
merswith the humanhistamineH4 receptor (H4R). BILF1 inhib-
ited histamine-induced Gi-mediated signaling by H4R, how-
ever,without affectinghistaminebinding to this receptor. These
data indicate that functional cross-regulation of Gi-coupled
GPCRs by BILF1 is at the level of G proteins, even though these
GPCRs are assembled in hetero-oligomeric complexes.
G protein-coupled receptors (GPCRs)2 are integral mem-
brane proteins that play a predominant role in sensory trans-
duction and communication between cells. Specific binding of
an extracellular messenger molecule (i.e. ligand) induces a con-
formational change in the GPCR protein, which allows intra-
cellular coupling and activation of G proteins (1). These G pro-
teins relay the message to downstream effector enzymes
resulting in the activation of a broad range of cellular responses.
The human genome encodes 800 different GPCRs that are
responsive to a plethora of endogenous (e.g. ions, lipid media-
tors, biogenic amines, amino acid, peptides, and glycoproteins)
and exogenous (e.g. odorants, tastants, and light) ligands (2).
Not surprisingly, GPCRs regulate nearly all physiological pro-
cesses in our body. Most cells express 5–20 different GPCRs,
which can bemixed andmatched variably in different cell types
(3). Cell type-specific GPCR expression profiles determine the
spatiotemporal responsiveness of these cells to ligands in the
extracellular environment.
GPCRs have long been considered to exist and function as
monomeric proteins. However, during the last decade increas-
ing evidence has indicated that GPCRs can interact physically
with each other. In fact, the class C GPCR, GABAB receptor,
and the sweet and umami taste receptors, TLR1–3, are obliga-
tory heterodimers. Importantly, heteromerization of GPCR
subtypes allows mutual regulation of the functional character-
istics of the individual partners, including receptor trafficking,
ligand binding, and receptor coupling to intracellular signaling
pathways (4). Hitherto, understanding of the molecular mech-
anism of GPCR heteromers in relation to the recruitment of
intracellular signaling complexes is still limited and sometimes
even contradictory. Given the dimension of aGPCR in compar-
ison to G protein and -arrestin, it has been suggested that a
GPCR dimer might provide the most appropriate docking sur-
face for heterotrimeric G protein or -arrestin coupling (5).
Indeed, the human leukotriene B4 receptor BLT1 was shown to
exist as a pentameric complex consisting of a BLT1 homodimer
and one heterotrimeric G protein (6). Nonetheless, only one of
the two BLT1 protomers within this receptor dimer complex
needs to be active to induce G protein coupling (7). Similar asym-
metry in receptor activity has been observed within various other
homo- and heterodimeric receptor complexes (8–10). Both rho-
dopsin and2-adrenergic receptors are organized as homodimers
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(11, 12). However, reconstitution of rhodopsin and 2-adrenergic
receptor monomers in high density lipoprotein particles does not
impair their capacity to activate G proteins (13, 14). In addition,
the neurotensin receptor NTS1 activates G proteins more effi-
ciently as a monomer than as a homodimer (15).
In addition, or alternatively, to cross-modulation of agonist-
induced signalingwithinGPCRdimers, activation of oneGPCR
subtype can affect the functioning of co-expressed GPCRs
through downstream cross-talk of their intracellular signaling
pathways (16–18) and/or heterologous desensitization (19).
Human - and -herpesviruses have one or more genes
encoding for GPCR proteins that are expressed on the mem-
brane of human cells upon viral infection (20). Recently, we
demonstrated that the Epstein-Barr virus (EBV)-encoded
GPCR BILF1 can form heterodimers with human chemokine
receptors (21).
In the current study we further explore the interaction
between BILF1 and the human chemokine receptor CXCR4.
Using bimolecular luminescence complementation (BiLC) and
bimolecular fluorescence complementation (BiFC) in tandem
with bioluminescence resonance energy transfer (BRET) detec-
tion, we demonstrate that the orphan receptor BILF1 forms
higher order hetero-oligomers with CXCR4. In addition, we
show that BILF1 impairs binding of the chemokine CXCL12 to
CXCR4 in a ligand-independent (constitutive) manner and,
consequently, attenuates CXCL12-induced CXCR4 signaling.
EXPERIMENTAL PROCEDURES
Materials—Cell culture media, trypsin, and accutase were
obtained from PAA Laboratories (Pasching, Austria). Forsko-
lin, pertussis toxin, and -bungarotoxin-tetramethylrhodam-
ine (TMR-BTX) were purchased from Sigma-Aldrich. Peni-
cillin and streptomycin were obtained from Lonza (Verviers,
Belgium). Fetal bovine serum was purchased from Integro BV
(Dieren, The Netherlands). HEPES and D-luciferin were pur-
chased from Duchefa Biochemie (Haarlem, The Netherlands).
Bovine serum albumin fraction V (BSA) was obtained from
Roche Applied Science. [125I]-Bungarotoxin (BTX; 2200
Ci/mmol), [125I]CXCL12 (2200 Ci/mmol), [3H]histamine (18.1
Ci/mmol), and [35S]GTPS (1250 Ci/mmol) were obtained
from PerkinElmer Life Sciences. CXCL12 was purchased from
PeproTech (RockyHill, NJ), andVectashieldHardsetmounting
medium was obtained from Vector Laboratories.
Plasmids—DNA plasmids encoding the full-length and
complementation protein fragments of mVenus and Rluc8
were kindly provided by Dr. J. A. Javitch (Columbia University,
NewYork) (22). To facilitate subcloning, the 5-end of the orig-
inal 24-amino acid N-terminal linker sequence of these con-
structs was substituted with SpeI/NotI restriction endonucle-
ase sites by PCR, whereas the XhoI/XbaI sites were introduced
immediately downstream of the stop codon. FLAG-BILF1,
BBS-BILF1, BBS-BILF1-Rluc, and CXCR4-eYFP constructs
have been described previously (21). Fusion of the 13-amino
acid BTX-binding site (BBS) to the N terminus of BILF1
allows detection of receptor proteins by high affinity binding of
TMR-BTX or [125I]BTX. Rluc- and eYFP-encoding se-
quences were substituted with the DNA sequence of the full-
length and complementation protein fragments of Rluc8 and
mVenus using NotI and XbaI. The BILF1-K3.50A construct was
kindly provided by Dr. P. Beisser (Maastricht University Med-
ical Center, The Netherlands). The K3.50A mutation was sub-
cloned into BBS-BILF1/pcDEF3 by using Psp5II andVan9Il. All
constructs were verified by DNA sequencing. DNA encoding
the GABAB2-YFP fusion protein was a gift from Dr. J.-P. Pin
(Institut de Génomique Fonctionnelle, Montpellier, France).
Myc-tagged human histamineH4 receptor (myc-H4R) has been
described previously (23). The cyclicAMP-responsive element-
binding protein (CREB)-driven luciferase reporter gene plas-
mid pTLNC-21CRE was provided by Dr. W. Born (National
Jewish Medical and Research Center, Denver, CO). The cDNA
clone for human Gi1 was obtained from the Missouri S&T
cDNA Resource Center.
Cell Culture and Transfection—HEK293T cells were cul-
tured and transiently transfected with the indicated amounts of
DNA using 25-kDa linear polyethylenimine (Polysciences) as
described previously (21). Total DNA in gene dosing experi-
ments was kept constant by the addition of “empty” pcDEF3
plasmid.
Protein Fragment Complementation and BRET—HEK293T
cells were cultured and transfected in white-bottomed 96-well
plates. BiFC andBiLCweremonitored 48 h after transfection as
fluorescence (excitation at 498 nm and emission at 535 nm; 1-s
recording) and luminescence in the presence of 5 M coelen-
terazine H (emission at 460 nm; 1-s recording at 5min after the
addition of coelenterazine H (Promega)), respectively, using a
Victor3 1420 multilabel plate reader (PerkinElmer Life Sci-
ences). BRET was measured as described previously (21).
BiFC Microscopy—HEK23T cells were cultured and trans-
fected in 10-cm dishes. Twenty-four hours after transfection
cells were seeded on poly-L-lysine-coated coverslips in 6-well
plates. The next day, coverslips were labeled with 0.6 MTMR-
BTX in phosphate-buffered saline for 30min at room temper-
ature. Coverslips were then washed twice with phosphate-buff-
ered saline and once with H2O. To stain cell nuclei, 4,
6-diamidino-2-phenylindole (1 g/l) was added during the
last wash step. Coverslips were placed on a microscope slide
with one drop of Vectashield Hardset mounting medium and
stored at 4 °C until further analysis. Cells were visualized using
an Olympus FSX100 fluorescence microscope.
Enzyme-linked Immunosorbent Assay (ELISA)—Forty-eight
hours after transfection, protein expression was determined by
ELISA as described previously (24), with some minor changes.
Cells were incubated with the anti-CXCR4 monoclonal IgG2a
antibody, 12G5 (fusin) (1:800 dilution, 200 g/l, Santa Cruz
Biotechnology). As secondary antibody, horseradish peroxi-
dase-conjugated goat anti-mouse antibodies (1:2000 dilution,
Bio-Rad) were used. Peroxidase activity was visualized using
the 3,3,5,5-tetramethylbenzidine liquid substrate system
(Sigma-Aldrich).
Radioligand Binding—Whole cell binding was performed
48 h after transfection using 0.25 nM [125I]BTX as described
(21). Alternatively, cell membrane fractions from HEK293T
cells expressingCXCR4, BBS-BILF1, and/or BBS-BILF1-K3.50A
were prepared as described previously (24). Cell membranes
were incubated in 96-well plates in binding buffer (50 mM
HEPES, 1 mM CaCl2, 5 mM MgCl2, and 100 mM NaCl, pH 7.4)
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containing 0.2% BSA with 0.25 nM [125I]BTX or 0.08 nM
[125I]CXCL12 for 2 h at room temperature. Aspecific radioli-
gand binding was determined in the presence of 0.1 M unla-
beled BTX or CXCL12, respectively. Incubations were termi-
nated by filtration through Unifilter GF/C plates (PerkinElmer
Life Sciences) presoaked in 0.3% polyethylenimine and washed
three times with ice-cold binding buffer supplemented with 0.5
M NaCl. Radioactivity was measured using a MicroBeta Trilux
(PerkinElmer Life Sciences).
[35S]GTPS Binding—Cell membranes were incubated in
96-well plates in assay buffer (50mMHEPES, 10mMMgCl2, and
100 mM NaCl, pH 7.2), 5 g of saponin, 3 M GDP, and 0.5 nM
[35S]GTPS, in the absence or presence of 100 nMCXCL12, in a
total volume of 100 l. Reactions were incubated at room tem-
perature for 1 h and then terminated by filtration through Uni-
filter GF/B plates (PerkinElmer Life Sciences) andwashed three
times with ice-cold washing buffer (50 mM Tris-HCl and 5 mM
MgCl2, pH 7.4). Radioactivity was measured using a Microbeta
Trilux.
CREB Reporter Gene Assay—HEK293T were cultured in
white-bottomed 96-well plates and co-transfected with 500 ng
of reporter gene plasmid, pTLNC-21CRE (consisting of a firefly
luciferase gene controlled by a 21-cAMP-responsive element-
containing promoter) and 10–50 ng of CXCR4, BBS-BILF1,
and/or BBS-BILF1-K3.50A DNA/106 cells. Forty-eight hours
after transfection, the culture medium was aspirated, and cells
were stimulated with 100 nM CXCL12 in culture medium sup-
plementedwith 1M forskolin for 6 h at 37 °C. Luciferase activ-
ity was measured as described previously (25).
Data Analysis—All experiments were repeated using cells
from independent transfections. Curve fitting and statistical
analyses were performed using GraphPad Prism 4 software.
RESULTS
BILF1 Forms Higher Order Hetero-oligomers with CXCR4—
The optimized BRET sensors Rluc8 (26) andmVenus (27) were
used to show close proximity between BILF1 and CXCR4.
Bioluminescence and fluorescence emitted by GPCR-BRET
sensor constructs increased linearly with increasing receptor
numbers (data not shown), confirming previous observations
(28, 29). BBS-BILF1 expression was determined by [125I]BTX
binding, whereas expression of CXCR4 constructs was quanti-
fied by ELISA. Both BBS-BILF1-Rluc8 andCXCR4-Rluc8 emit-
ted significantly (p  0.0001) more light per receptor number
than the previously described BBS-BILF1-Rluc and CXCR4-
Rluc, respectively (Fig. 1A) (21).On the other hand, themVenus
variants of BILF1 and CXCR4 were less or equally fluorescent
per receptor, respectively, as compared with their previously
used eYFP counterparts (Fig. 1B) (21). BRET experiments were
performed using these optimized BRET sensor constructs by
transfecting 1 ng of receptor-Rluc8 (donor) DNA in combina-
tion with 0–1000 ng of receptor-mVenus (acceptor) DNA/106
cells. Saturable BRET signals indicate specific interactions
between BILF1-BILF1, BILF1-CXCR4, and CXCR4-CXCR4
BRET pairs, which is consistent with our previous work (21)
(Fig. 1, C and D). Typically, BRET signals were higher for both
BILF1 and CXCR4 homodimers as compared with BILF1-
CXCR4 heterodimers. The latter was independent of the BRET
sensor orientation, as swapping the sensors between BILF1 and
CXCR4 yielded a similar BRET signal for the heterodimeric
interaction. Nonspecific receptor interactions as a conse-
quence of random collisions were observed as quasi-linear
BRET signals in cells co-expressing BBS-BILF1-Rluc8 or
CXCR4-Rluc8 with GABAB2-YFP (Fig. 1, C and D).
To study higher order protein-protein interactions in living
cells, we used BiLC and BiFC approaches in combination with
BRET. N- and C-terminal complementation fragments of the
optimized BRET couple Rluc8 and mVenus have been devel-
oped by the Javitch laboratory (22). Rluc8 was split into L1
(amino acids 1–229) and L2 (amino acids 230–311), whereas
mVenus was split in V1 (amino acids 1–155) and V2 (amino
acids 156–240). Expression of the individual receptor-L1, -L2,
-V1, and -V2 fusion constructs inHEK293T cells did not signif-
icantly increase luminescence or fluorescence above back-
ground (data not shown), confirming previous observations
(22). Co-expression of BBS-BILF1-L1 with CXCR4-L2 or
CXCR4-L1 with BBS-BILF1-L2 resulted in BiLC (Fig. 2, A and
B). Functional reconstitution of the Rluc8 protein occurred
only when the L1 and L2 fragments were brought into close
FIGURE 1. Detection of BILF1 and CXCR4 heterodimers by BRET. A and B,
HEK293T cells were transfected with BBS-BILF1 or CXCR4 BRET fusion con-
structs. After 48 h, receptor surface expression (RSE) levels were quantified for
BBS-BILF1 and CXCR4 by [125I]BTX binding or ELISA, respectively, on whole
cells. Measured Rluc (gray bars) and Rluc8 (white bars) luminescence (A) and
eYFP (gray bars) and mVenus (white bars) fluorescence (B) are normalized for
RSE. C and D, HEK293T cells were transfected with fixed amounts of the BRET
donor construct BBS-BILF1-Rluc8 (C) and CXCR4-Rluc8 (D) DNA and increas-
ing amounts of BRET acceptor constructs BBS-BILF1-mVenus (E), CXCR4-
mVenus (F), and GABAB2-YFP () DNA. The BRET ratio is defined as
[BRET/luminescence] in the presence of acceptor constructs minus [BRET/
luminescence] in the absence of acceptor constructs. BRET ratio was plotted
as a function of the increasing acceptor/donor ratio as quantified by fluores-
cence and luminescence, respectively. Data are means  S.E. of representa-
tive experiments performed at least three times in triplicate. Significant dif-
ferences (p  0.0001) were determined using a t test and are indicated by
asterisks. Curves were fitted using nonlinear regression, assuming a single
binding site. au, arbitrary units.
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proximity by the proteins to which
they were fused, confirming that
BILF1 and CXCR4 form het-
erodimers. Co-expression of BBS-
BILF1-L1 and BBS-BILF1-L2 in a
1:1 ratio at a total receptor surface
level equal to that of BBS-BILF1-
Rluc8 (Fig. 2C) yielded a 3.3-fold
lower BiLC signal compared with
BBS-BILF1-Rluc8 luminescence
(Fig. 2D). Considering that three
populations of BILF1 homodimers
exist in cells co-expressing BBS-
BILF1-L1 and BBS-BILF1-L2 (i.e.
L1/L1, L1/L2, and L2/L2), the
observed BiLC signal suggests that
all BILF1 receptors are involved in
dimers. Reconstitution of mVenus
by BBS-BILF1-V1 and CXCR4-V2
and vice versa, in combination with
the binding of TMR-BTX to sur-
face-expressed BILF1 (Fig. 2, E–H),
revealed that BILF1-CXCR4 het-
erodimers are localized at the cell
surface (Fig. 2H) confirming our
previous findings (21). The punctu-
ated green areas are newly formed
intracellular BILF1/CXCR4 het-
erodimers, as indicated by the ab-
sence of co-localized TMR-BTX
fluorescence (Fig. 2, F–H). On the
other hand, internalized receptor
complexes are indicated by intracel-
lularly localized TMR-BTX-la-
beled BILF1/CXCR4 heterodimers.
Higher order BILF1-CXCR4 pro-
tein complexes were detected by measuring BRET between
reconstituted L1/L2 and V1/V2 heterodimers of BILF1 and
CXCR4. To this end, cells were co-transfected with constant
amounts of the split Rluc8 constructs (i.e. 10 ng of both L1 and
L2 construct DNA/106 cells) with increasing amounts of the
split mVenus constructs (i.e. 0–950 ng of both V1 and V2 con-
struct DNA/106 cells). A saturable BRET signal was observed
between all combinations of complemented Rluc8 and mVe-
nus, indicating that BILF1 and CXCR4 form oligomeric com-
plexes consisting of at least four protomers (Fig. 3).
Constitutively Active BILF1 Inhibits CXCL12 Binding to
CXCR4—To investigate whether hetero-oligomerization of
BILF1 and CXCR4 affects chemokine (i.e. CXCL12) binding to
the latter, BBS-BILF1 (2.5 or 25 ng DNA/106 cells) and CXCR4
(50 ng DNA/106 cells) were co-expressed in HEK293T cells.
Radioligand binding assays were performed onmembrane frac-
tions expressing individual or both receptors. CXCR4 expres-
sion was evaluated by ELISA on whole cells of the same trans-
fection. BBS-BILF1 significantly impaired binding of CXCL12
to CXCR4 in an expression level-dependent manner, without
having a major effect on CXCR4 protein levels (Fig. 4). The
slight reduction in CXCR4 protein expression at 25 ng of BILF1
FIGURE 2. Detection of BILF1 and CXCR4 heterodimers by BiLC and BiFC. A, HEK293T cells were co-trans-
fected with 10 ng of BBS-BILF1-L1 and 1–50 ng of CXCR4-L2 DNA/106 cells (E) or 10 ng of BBS-BILF1-L2 and
1–50 ng of CXCR4-L1 (F). B, HEK293T cells were co-transfected with 10 ng of CXCR4-L1 and 1–50 ng of
BBS-BILF1-L2 (E) or 10 ng of CXCR4-L2 and 1–50 ng of BBS-BILF1-L1 (F). Luminescence was measured
after 48 h and plotted as a function of BBS-BILF1 and CXCR4 RSE as determined by [125I]BTX binding and
ELISA, respectively. C and D, HEK293T cells were co-transfected with the split BiLC constructs BBS-BILF1-L1
and BBS-BILF1-L2 or BBS-BILF1-Rluc8. The RSE of the BBS-BILF1 fusion proteins was determined by
[125I]BTX binding (C), and luminescence was measured in parallel (D). E–H, HEK293T cells were co-trans-
fected with 10 ng of BBS-BILF1-V1 and CXCR4-V2 DNA/106 cells and cultured on poly-L-lysine-coated
coverslips. After 48 h, the BBS-BILF1 protomer was labeled with TMR-BTX as depicted in the schematic
(E). Reconstituted mVenus (green (F)), TMR-BTX labeling (red (G)), and co-localization (yellow (H)) were
analyzed using an Olympus FSX100 fluorescence microscope. Nuclei were stained with 4,6-diamidino-2-
phenylindole (blue). Data are means  S.E. of representative experiments performed at least three times
in triplicate. rlu, relative light units.
FIGURE 3. Detection of BILF1 and CXCR4 hetero-oligomers by BiLC/
BiFC-BRET. A, HEK293T cells were co-transfected with 10 ng of DNA from
the BiLC constructs BBS-BILF1-L1 and CXCR4-L2 (1:1) and 0 –950 ng of DNA
from the BiFC constructs BBS-BILF1-V1 and CXCR4-V2 (E) or CXCR4-V1 and
BBS-BILF1-V2 (F) (1:1)/106 cells. B, BiLC constructs CXCR4-L1 and BBS-
BILF1-L2 in combination with BiFC constructs BBS-BILF1-V1 and CXCR4-V2
(E) or CXCR4-V1 and BBS-BILF1-V2 (F). After 48 h, fluorescence, lumines-
cence, and BRET were measured. The BRET ratio was plotted as a function
of the increasing reconstituted acceptor (BiFC)/donor (BiLC) ratio as quan-
tified by fluorescence and luminescence, respectively. Data are represent-
ative of at least three independent experiments each performed in
triplicate.
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DNA transfection was not the cause of the loss of CXCL12
binding (Fig. 4, B and C), as individually expressed CXCR4 at
comparable levels still boundCXCL12 (supplemental Fig. I). To
determine whether the constitutive activity of BILF1 hampers
CXCL12 binding to CXCR4 by, for example, inducing a cross-
conformational change in the assembled CXCR4 protomer,
similar binding experiments were performed on membranes
co-expressing the constitutively inactive mutant BBS-BILF1-
K3.50A (30). BILF1-K3.50A has a propensity similar to BILF1 to
heterodimerize with CXCR4 (supplemental Fig. II). BBS-
BILF1-K3.50A was co-expressed with CXCR4 at levels compa-
rable to that of BILF1 (Fig. 4A). Similar to BILF1, the transfec-
tion of 25 ng of BBS-BILF1-K3.50A DNA/106 cells resulted in a
slight reduction of CXCR4 expression as measured with the
anti-CXCR4 antibody 12G5 (Fig. 4B). However, BBS-BILF1-
K3.50A had no significant effect on CXCL12 binding to mem-
branes co-expressing CXCR4, as compared with membranes
expressing only CXCR4 (Fig. 4C).
Constitutively Active BBS-BILF1 Inhibits CXCL12-induced
CXCR4 Signaling through Gi/o Proteins—To evaluate the
effect of BBS-BILF1 co-expression onCXCR4-mediatedG pro-
tein activation, [35S]GTPS binding to membranes expressing
both receptors was measured and compared with membranes
that were derived fromHEK293T cells that express either BBS-
BILF1 or CXCR4 and were mixed in an 1:1 ratio (Fig. 5A). Con-
stitutive binding of [35S]GTPS was observed in both co-ex-
pressing and mixed membranes as a result of constitutive












































































FIGURE 4. BILF1 inhibits CXCL12 binding to CXCR4. HEK293T cells were
co-transfected with 50 ng of CXCR4 and 0, 2.5 or 25 ng of BBS-BILF1 or BBS-
BILF1-K3.50A DNA/106 cells. A, DNA dose-dependent BBS-BILF1 and BBS-
BILF1-K3.50A expression was shown by [125I]BTX binding to membrane
preparations. B, CXCR4 expression was determined in parallel by ELISA.
C, [125I]CXCL12 binding on the same membrane set. Data are means  S.E.
from three independent experiments, each performed in triplicate. Statistical
differences between CXCR4 in the absence or presence of BBS-BILF1-(K3.50A)
were determined using a one-way ANOVA followed by a Bonferroni’s multi-
ple comparison test (*, p  0.05; **, p  0.001).
FIGURE 5. BILF1 inhibits CXCL12-induced G protein activation by CXCR4.
HEK293T cells were transfected with 50 ng of CXCR4 and/or 20 ng of BBS-
BILF1 DNA or BBS-BILF1-K3.50A DNA/106 cells. A, CXCL12-induced (0.1 M)
binding of [35S]GTPS was measured in membranes derived from cells co-
transfected with BBS-BILF1 and CXCR4 (CO) or from cells expressing either
BBS-BILF1 or CXCR4 that were mixed prior to membrane preparation (MIX) in
response to a 1-h incubation with buffer (black bars), 0.1 M CXCL12 (gray
bars), or 0.1 M CXCL12 and 10 M AMD3100 (white bars). Mock-transfected
cells were used as control. B, binding of [35S]GTPS to membranes expressing
the indicated receptor constructs was determined in response to vehicle
treatment or 0.1 M CXCL12. To emphasize changes in ligand-induced signal-
ing, [35S]GTPS binding was normalized to vehicle treatment for each of the
membrane preparations and consequently is shown as fold basal. Data are
means  S.E. from three independent experiments, each performed in tripli-
cate. Statistical differences were determined using a one-way ANOVA fol-
lowed by a Bonferroni’s multiple comparison test (*, p  0.05; **, p  0.001).
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signaling of BBS-BILF1 (Fig. 5A and supplemental Fig. III). Sub-
sequent stimulation of membranes co-expressing BBS-BILF1
and CXCR4 with 0.1 M CXCL12 did not increase basal
[35S]GTPS binding (Fig. 5, A and B). In contrast, CXCL12
significantly increased [35S]GTPS binding to mixed mem-
branes, which can be fully blocked by the CXCR4 antagonist
AMD3100 (10 M) (Fig. 5A). CXCL12 induced a significant
1.64-fold increase in [35S]GTPS binding to CXCR4-express-
ing membranes as compared with vehicle treatment (Fig. 5B).
In contrast, CXCL12 did not change [35S]GTPS binding to
mock, BBS-BILF1-, and BBS-BILF1-K3.50A-expressing mem-
branes differently from vehicle treatment (Fig. 5B and sup-
plemental Fig. III). Interestingly, co-expression of the constitu-
tively inactive mutant BBS-BILF1-K3.50A with CXCR4 did not
affect CXCL12-induced G protein activation, resulting in a
similar increase in [35S]GTPS binding as observed in mem-
branes that express CXCR4 alone (Fig. 5B and supplemental
Fig. III).
Both CXCR4 and BBS-BILF1 signal through Gi/o proteins
(25, 31, 32). To examine downstream signaling, HEK293T cells
were co-transfected with a CREB-driven reporter gene plasmid
and CXCR4 and/or BBS-BILF1. Receptor surface expression of
CXCR4 was determined by ELISA. BBS-BILF1 slightly reduced
CXCR4 expression levels (Fig. 6A). To detect Gi/o-mediated
inhibitory signaling to CREB, intact cells were incubated with 1
M forskolin (FSK) leading to a direct activation of adenylyl
cyclase. Expression of BBS-BILF1 resulted in a ligand-indepen-
dent decrease of this FSK-induced CREB activity (supplemen-
tal Fig. IVA) as shown previously (25, 32). Stimulation of
CXCR4-expressing cells with 0.1 M CXCL12 resulted in a sig-
nificant decrease of FSK-induced CREB activity as compared
with vehicle treatment (Fig. 6B and supplemental Fig. IVB).
However, co-expression of the constitutively active BBS-BILF1
with CXCR4 significantly attenuated this CXCL12-induced
inhibition of CREB activity (Fig. 6B). In contrast, the constitu-
tively inactive mutant BBS-BILF1-K3.50A inhibited CXCL12-
induced CXCR4 signaling to a much lesser extent than BBS-
BILF1. Overnight pretreatment of the cells with pertussis toxin
(100 ng/l) abolished all BBS-BILF1- and/or CXCR4-mediated
inhibition of FSK-induced CREB activity (supplemental Fig. V),
confirming signaling through Gi/o proteins (25, 31, 32).
Constitutively Active BBS-BILF1 Competes with Co-ex-
pressed GPCR for Gi/o Proteins—The difference in efficacy
between the constitutively active BBS-BILF1 and constitutively
inactive mutant BBS-BILF1-K3.50A in regard to CXCR4 signal-
ingmight be related to the stabilization of distinct CXCR4 con-
formations in their respective hetero-oligomeric complexes,
resulting in changed CXCL12 binding and, consequently, sig-
naling.Alternatively, the constitutively active BBS-BILF1might
scavenge Gi/o proteins to such an extent that only a very lim-
ited amount of G proteins are available for coupling to CXCR4.
To evaluate the role of G protein coupling on CXCL12 binding
toCXCR4, [125I]CXCL12 binding experiments were performed
in the presence of 3 MGTPS. Binding of CXCL12 to CXCR4
was fully inhibited by preventing G protein coupling to the
receptor (Fig. 7A). On the other hand, co-expression of addi-
tional Gi1 protein with CXCR4 and BBS-BILF1 restored
CXCR4-mediated inhibition of CREB activity in response to
CXCL12 (Fig. 7B) without significantly affecting receptor sur-
face expression (Fig. 7C). To further explore whether constitu-
tive BBS-BILF1 signaling affects the functioning of other
GPCRs that couple to Gi/o proteins, HEK293T cells were
transfected with BBS-BILF1 or BBS-BILF1-K3.50A and/or
human H4R. BBS-BILF1 and H4R receptor were expressed at
the cell surface and formed heterodimeric complexes as
revealed by BiFC, although internalized TMR-BTX-labeled
BBS-BILF1/H4R heterodimers were observed as well (Fig. 8,
A–D). Histamine (10 M) significantly decreased FSK-induced
CREB activity in HEK293T cells expressing H4R, as compared
with vehicle treatment, without affecting BBS-BILF1 signaling
to CREB (Fig. 8E). Co-expression of BBS-BILF1 with H4R abol-
ished the histamine responsiveness of H4R, whereas BBS-
BILF1-K3.50A did not disturb histamine-induced signaling to
CREB (Fig. 8E). In contrast to [125I]CXCL12 binding toCXCR4,
[3H]histamine binding to hH4R-expressing membranes was
not affected by BBS-BILF1 (Fig. 8F), which confirms that hista-
FIGURE 6. BILF1 inhibits CREB activation by CXCR4 in response to
CXCL12. A, CXCR4 RSE in HEK293T cells transfected with CXCR4 (50 ng/106
cells), BBS-BILF1 (25 ng/106 cells), and/or BBS-BILF1-K3.50A (25 ng/106 cells) as
determined by ELISA. B, FSK-induced CREB activity was measured in parallel
in the absence or presence of 0.1 M CXCL12. To emphasize changes in
ligand-induced signaling, CREB activity is normalized to vehicle treatment for
each of the transfectants and consequently shown as fold basal. Data are
means  S.E. of representative experiments performed at least three times in
triplicate. Significantly changes in CXCR4 RSE as compared with CXCR4-only
cells are determined by a one-way ANOVA followed by a Bonferroni’s multiple
comparison test (A). Significant changes in CREB activity in the presence of
CXCL12 as compared with mock cells were determined by the same statistical
analysis (*, p  0.05; **, p  0.001).
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mine binding to H4R is not affected by G protein uncoupling
with GTPS (Fig. 8G) (33).
DISCUSSION
EBV hides latently in memory B cells in 95% of all human
beings. Terminal differentiation of these infected memory B
cells into antibody-secreting plasma cells reinitiates the repli-
cative cycle of EBV, ultimately leading to the production of new
infectious virions (34). One of the viral genes that is up-regu-
lated during this replicative cycle is the EBV-encoded GPCR
BILF1 (25, 32, 35). BILF1 constitutively signals to CREB and
NF-B via pertussis toxin-sensitive Gi/o protein-mediated
pathways (25, 32), as corroborated in this study by, for example,
the constitutive increase of GTPS binding to BILF1-express-
ing membranes.
Previously we showed that BILF1 forms heteromeric com-
plexes with human chemokine receptors that are expressed
endogenously on plasma B cells (21). However, the previously
used time-resolved BRET and co-immunoprecipitation meth-
ods could not distinguish dimeric from oligomeric assemblages
(21). By combining BiFC and BiLC with BRET measurements,
we now showed that heteromeric complexes between BILF1
andCXCR4 consist of at least four interactingGPCRproteins at
the same time. Such oligomeric organization has been observed
for native rhodopsin in disc membranes of rod outer segments
by using atomic force microscopy (11) but have also been
observed between class C GPCRs GABAB1 and GABAB2 (36)
and between various class A GPCRs using various modifica-
tions and/or combinations of resonance energy transfer-based
methods as well as cross-linking experiments (22, 37–41).
Hitherto, however, the functional significance and/or necessity
of oligomeric receptor complexes versus receptor dimers have
remained puzzling. For example, the dopamine D2 receptor is
organized as homo-oligomers consisting of at least four recep-
tors (22). However, co-expression of a non-signaling dopamine
D2 receptor-G protein fusion construct with wild type dopa-
mine D2 receptor revealed that a functional signaling complex
consists of two GPCR protomers and a single heterotrimeric G
protein (9). Moreover, dimerization of obligatory GABAB het-
erodimers attenuated G protein coupling in response to GABA
as comparedwith signaling of individual GABAB heterodimers,
suggesting that the level of oligomerization might control sig-
naling efficacy (36).
Co-expression of BILF1 and CXCR4 in HEK293T cells
impaired CXCL12 binding to CXCR4. Previously, CXCR4 was
shown to heterodimerize with the chemokine receptors CCR2
(42), CCR5 (41), and CXCR7 (43). The chemokines CCL2 and
CCL4 do not interact with CXCR4. However, CCL2 and CCL5
inhibit CXCL12 binding to CXCR4 upon co-expression of
CCR2 and CCR5, respectively (41, 42). Likewise, CXCL12
inhibits CCL2 and CCL4 binding to cells co-expressing CCR2
or CCR5 with CXCR4. The observed negative binding cooper-
ativity across these chemokine receptor heterodimers is the
consequence of allosteric modulation of the ligand-binding site
conformation of one protomer upon binding of a ligand to the
other protomer, as revealed by a significant acceleration of
radioligand dissociation from one protomer under infinite
tracer dilution conditions in the presence of unlabeled chemo-
kine or nonpeptidergic ligand of the second protomer (41, 42).
Such transmission of a conformational change across a
receptor heterodimerwas shown directly between the-opioid
receptor (MOR) and the 2A-adrenergic receptor (2A-AR).
Binding ofmorphine toMOR induces a conformational change
in the norepinephrine-occupied 2A-AR, as detected by a
change in norepinephrine-induced FRET between two fluo-
phores incorporated into the C-tail and intracellular loop 3 of
2A-AR, respectively (10). As a consequence, norepinephrine-
induced signaling of 2A-AR to G proteins is inhibited within
milliseconds upon binding of morphine to MOR. In addition,
simultaneous stimulation of these transfected cells or primary
spinal cord neuronswithMOR and2A-AR agonists attenuates
extracellular signal-regulated kinases 1 and 2 (ERK1/2) phos-
phorylation as compared with stimulation with either of these
agonists (10) (44). Hence, the activation of one protomer by
agonist binding is sufficient to induce signal transduction,
whereas agonist occupancy of both protomers attenuates
receptor dimer-mediated signaling. On the other hand, stabili-
FIGURE 7. BILF1 inhibits CXCL12-induced CXCR4 signaling by scavenging
Gi proteins. A, [
125I]CXCL12 binding to CXCR4-expressing membranes in
the absence and presence of 3 M GTPS. B, FSK-induced CREB activity in cells
expressing the indicated receptors in the absence or presence of co-trans-
fected Gi1 proteins in response to vehicle or 0.1 M CXCL12 treatment.
CXCL12-modulated CREB activity is normalized to vehicle treatment for each
of the transfectants and consequently shown as fold basal. C, BBS-BILF1 and
CXCR4 RSE as determined by [125I]BTX binding or ELISA to whole cells,
respectively. Data are means  S.E. of representative experiments performed
at least three times in triplicate. Significant differences compared with FSK-
treated mock cells (gray bar (B)), unless otherwise specified, are indicated by
asterisks as determined using a one-way ANOVA followed by a Bonferroni’s
multiple comparison test (*, p  0.05; **, p  0.001).
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zation of the inactive conformation
of one protomer with an inverse
agonist results in an increase in ago-
nist-induced signaling of the associ-
ated protomer (9). This indicates
that a constitutively active pro-
tomer decreases agonist-induced
signaling of the second protomer
within the receptor dimer, which is
in line with the observed decrease
in responsiveness of CXCR4 to
CXCL12 when co-expressed with
the constitutively active BILF1. Be-
cause inverse agonists for BILF1 are
yet to be identified, a constitutively
inactive mutant of BILF1 was used
to evaluate the role of constitutive
receptor activity in this trans-inhibi-
tion across the BILF1-CXCR4 het-
eromer. Lysine 3.50 (Ballosteros-
Weinstein numbering) is part of the
EKT motif, which is the BILF1 vari-
ant of the highly conserved (E/D)RY
motif present in class AGPCRs (45).
Structural and mutational analysis
of various class A GPCRs indicated
that the (E/D)RY motif is involved
in constraining the GPCR in an
inactive conformation. This motif
undergoes structural rearrange-
ment upon receptor activation,
allowing Arg3.50 to directly interact with the G protein (1).
Non-conservative mutations of Arg3.50 impair G protein cou-
pling of most GPCRs, which is generally accompanied with a
loss of high affinity agonist binding, suggesting that Arg3.50
mutants indeed adopt an inactive conformation (45). Previ-
ously it was shown that BILF1-K3.50A did not constitutively
signal to NF-B (30). Co-expression of the constitutively inac-
tive BILF1-K3.50Awith CXCR4 did not affect CXCL12-induced
CXCR4 signaling as compared with cells expressing only the
CXCR4 receptor. This suggests that propagation of the consti-
tutively active conformation from BILF1 to the associated
CXCR4 may indeed hamper CXCL12 binding to the latter. In
addition, the absence of cross-inhibition within the BILF1-
K3.50A/CXCR4 heteromer reveals that other domains of BILF1
are not involved in inhibiting CXCR4 functioning as observed
previously between the orphan GPR50 and theMT1 melatonin
receptor. The exceptionally long C-tail (300 amino acids) of
GPR50 inhibits protein recruitment to the GPR50/MT1 het-
erodimer, or it may scavenge intracellular proteins that nor-
mally interact with MT1; as a consequence melatonin binding
and G protein coupling to the MT1 protomer is inhibited (46).
BILF1 andCXCR4 both couple predominantly to pertussis tox-
in-sensitive Gi/o (Fig. 9) (25, 31, 32). In addition or alterna-
tively to cross-conformational inhibition of CXCR4 within a
BILF1/CXCR4 heteromer, the constitutive recruitment of
Gi/o proteins to BILF1may hamper the precoupling ofCXCR4
to this shared pool of Gi/o proteins (Fig. 9B). Importantly,
FIGURE 8. BILF1 forms heteromers with H4R and inhibits histamine-induced signaling without affecting
binding. A–D, HEK293T cells were co-transfected with 50 ng of H4R-V1 and BBS-BILF1-V2 DNA/10
6 cells and
cultured on poly-L-lysine-coated coverslips. After 48 h, the BBS-BILF1 protomer was labeled with TMR-BTX as
depicted in the schematic (A), and co-localization (yellow (D)) of reconstituted mVenus (green (B)) and TMR-
BTX (red (C)) was analyzed using an Olympus FSX100 fluorescence microscope. Nuclei were stained with
4,6-diamidino-2-phenylindole (blue). E, FSK-induced CREB activity in cells in the absence or presence of 10 M
histamine (HA) 48 h after transfection with 50 ng of Myc-H4R and/or 25 ng of BBS-BILF1 or BILF-K
3.50A DNA/106
cells. Histamine-induced CREB activity is normalized to vehicle treatment for each of the transfectants and conse-
quently shown as fold basal. F, [3H]histamine binding to membranes expressing the indicated receptors. G, [3H]his-
tamine binding to membranes expressing H4R in the presence of 10 M histamine or increasing concentrations
(0.3–10 M) of GTPS. The bar graphs represent the mean of pooled data from at least two experiments performed
in triplicate. Error bars indicate S.E. Significant differences are indicated by asterisks, as determined using a one-way
ANOVA followed by a Bonferroni’s multiple comparison test (*, p  0.05; **, p  0.01; ***, p  0.001).
FIGURE 9. Schematic representation of the inhibition of CXCR4 by the
constitutively active BILF1. A, CXCL12 binding to CXCR4 is Gi protein-de-
pendent (a) and results in receptor and G protein activation (b). B, constitu-
tively active BILF1 heteromerizes with CXCR4 and may allosterically inhibit
CXCL12 binding to CXCR4 (c). Moreover, BILF1 constitutively recruits and acti-
vates Gi proteins (d). This scavenging prevents Gi proteins from interacting
with CXCR4, resulting in an inhibition of CXCL12 binding (e). C, the constitu-
tively inactive mutant BILF1-K3.50A is not able to cross-inhibit CXCL12 binding
to CXCR4 upon heteromerization (f). BILF1-K3.50A does not compete with
CXCR4 for available Gi proteins (g), allowing Gi protein-dependent CXCL12
binding to CXCR4 (h). For the sake of clarity, receptor homomers and olig-
omers are not shown in this figure.
Viral Hijacking of the Human CXCR4 Receptor















precoupledGproteins can allostericallymodulate agonist bind-
ing to the extracellular site of GPCRs (47, 48). In fact, G pro-
teins are strictly required for agonist binding to some
GPCRs, including CXCR4 and various other chemokine
receptors (Fig. 9A) (49–52). Supplementing BILF1/CXCR4-
co-expressing HEK293T cells with additional Gi1 proteins
overcame the BILF1-mediated inhibition of CXCR4 function-
ing, which, in combinationwith the inability of BILF1-K3.50A to
inhibit CXCR4, suggests that BILF1 attenuates CXCL12 bind-
ing to CXCR4 by constitutively scavenging Gi/o proteins (Fig.
9C). On the other hand, binding of histamine to the Gi-cou-
pled H4R was not affected by co-expression of BILF1, which is
in concert with the recent observation that histamine binding
to this receptor is G protein-independent (33). However, con-
stitutive BILF1 signaling abolished histamine-induced H4R
downstream signaling to CREB. Similar inhibitory cross-talk
was recently observed between MOR and the constitutively
active cannabinoid CB1 receptor, which both predominantly
signal via Gi/o proteins (17). DAMGO-induced MOR signal-
ing was inhibited by co-expressed CB1 receptor in a ligand-
independent manner. However, inhibiting constitutive CB1
receptor signaling to G proteins by co-incubation with an
inverse agonist (i.e. SR141716A) or site-directed mutagenesis
(i.e. CB1-D3.49N) restored MOR-mediated ERK1/2 phosphor-
ylation in response to DAMGO stimulation. As MOR and CB1
receptor are not assembled as heteromeric receptor complexes,
cross-regulation of MOR signaling by the CB1 receptor is on a
downstream intracellular level (17).
The chemokine receptor CXCR4 plays a key role in B cell
homing and is expressed on most B cell populations, including
plasma B cells (53). In addition, CXCR4 expression on tumor
cells, including B cell lymphoma and EBV-associated nasopha-
ryngeal carcinoma, allows these cells to metastasize toward
CXCL12-secreting organs (54, 55). The EBV-encoded GPCR
BILF1 forms hetero-oligomeric complexes with CXCR4 and
inhibits CXCL12 binding to this receptor as a consequence of
its constitutive activity. Attenuated migration of BILF1-ex-
pressing plasma B cells to CXCL12 gradients may be favorable
for EBV, allowing these cells to home and/or remain at sites that
are most optimal for viral replication and dissemination.
Although cross-conformational inhibition of CXCR4 by BILF1
within an oligomeric assembly cannot be excluded, the current
studies suggest that BILF1 inhibits the functioning of other
Gi/o-coupled GPCRs by constitutive scavenging of a shared
pool of Gi/o proteins, thereby preventing other GPCRs from
coupling to these G proteins (Fig. 9). Downstream cross-talk
between BILF1 and other Gi/o-coupled receptors does not nec-
essarily require or exclude hetero-oligomerization between
these receptors. Nonetheless, hetero-oligomerization of this
viral GPCR may well affect cellular receptor functioning on
novel or distinct signaling pathways and/or affect receptor traf-
ficking and mobility to, at, and from the cell surface, thereby
contributing to viral dissemination and/or virus-induced
pathologies.
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